BMC Urology最新文献

{"title":"A highly accurate nanopore-based sequencing workflow for culture and PCR-free microbial metagenomic profiling of urogenital samples.","authors":"Ben Ferneyhough, Matthew Roddis, Sam Millington, Jess Quirk, Chrysolin Clements, Sean West, Rosalind Schilizzi, Michael D Fischer, Nick J Parkinson","doi":"10.1186/s12894-025-01723-9","DOIUrl":"https://doi.org/10.1186/s12894-025-01723-9","url":null,"abstract":"<p><strong>Background: </strong>The application of molecular sequencing methods for microbiome profiling of biological samples are largely restricted to research use. However, they require significant resources such as time and cost and can suffer from amplification biases that may hamper interpretation of complex systems. These issues are also a barrier to adoption as standard clinical tools in, for example, diagnosis of urogenital infections. We report a new method that utilises third generation long-read nanopore sequencing to produce fast, accurate and fully quantitated metagenomic microbiome profiles. Here, as proof of principle, we apply this methodology to reassess the healthy urogenital microbiomes of asymptomatic female and male samples.</p><p><strong>Results: </strong>We show that our method is capable of accurately and reproducibly detecting both levels and composition of a synthetic mixture of ten species comprising known amounts of hard to lyse gram-positive bacteria, gram-negative bacteria and yeast. When applied to urogenital samples, we confirm previous observations that the female asymptomatic vaginal and urinary microbiomes are predominated by Gardnerella spp. or one of several Lactobacillus species (L. crispatus, L. gasseri, L. iners or L. jensenii) that conform to previously defined community state types. We show the tight relationship between vaginal and urinary populations of the same individual at both species and strain level, provide evidence for the previously observed dynamic nature of these microbiomes over a menstrual cycle and compare biomass and complexity of male and female urobiomes.</p><p><strong>Conclusions: </strong>We set out to develop an unbiased, amplification and culture-free, fully quantitative metagenomic microbiome profiling tool. Our initial observations suggest our method represents a viable alternative to existing molecular research tools employed in the analysis of complex microbiomes.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"41"},"PeriodicalIF":1.7,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary function, sexual function and quality of life after prostate low-dose-rate brachytherapy: a retrospective analysis.","authors":"Lauri Mäkelä, Arto Mikkola, Anssi Pétas, Harri Visapää","doi":"10.1186/s12894-025-01718-6","DOIUrl":"https://doi.org/10.1186/s12894-025-01718-6","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is most commonly diagnosed at a localized stage, allowing the majority of patients to receive curative treatment. The prognosis is often favorable, and there are numerous treatment options available, emphasizing the importance of assessing the side effects associated with each treatment. Low-dose-rate (LDR) brachytherapy is one such treatment option, supported by robust evidence regarding its efficacy and side effects. However, most published data primarily rely on physician-assessed toxicity, which may underestimate the patient's experience of side effects. This study aims to provide a comprehensive overview of the urinary side effects of LDR brachytherapy, with a focus on patient-reported outcomes.</p><p><strong>Methods: </strong>This retrospective study included 199 patients treated with LDR-brachytherapy years 2000-2012 at Helsinki University Hospital. Questionnaires used to assess urinary toxicity were International Prostate Symptom Score (IPSS) and The Danish Prostatic Symptom Score (DAN-PSS). Additionally, sexual function was assessed using the International Index of Erectile Function (IIEF) questionnaire. Urinary function was assessed with flowmetry, reporting peak flow rate and postvoid residual measurement.</p><p><strong>Results: </strong>There was a deterioration in urinary function during the first six months post-procedure, as evidenced by a decline in the urinary function questionnaires and uroflowmetry measurements. For most patients, this deterioration was transient, with median symptom scores returning to baseline after one year. A slight discrepancy was observed between patient-reported outcome measures and urinary function assessed by flowmetry.</p><p><strong>Conclusions: </strong>LDR brachytherapy is a well-tolerated treatment for localized prostate cancer. While many patients experience acute side effects that subside relatively quickly, there is a small risk of prolonged side effects. This risk should be thoroughly discussed with patients when making treatment decisions.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"40"},"PeriodicalIF":1.7,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia.","authors":"Chi-Hang Yee, Yuen-Hei Chung, Ivan Ching-Ho Ko, Chris Ho-Ming Wong, Alex Mok, Jeremy Yuen-Chun Teoh, Peter Ka-Fung Chiu, Chi-Fai Ng","doi":"10.1186/s12894-025-01717-7","DOIUrl":"10.1186/s12894-025-01717-7","url":null,"abstract":"<p><strong>Objective: </strong>Long-acting triptorelin (LAT) (22.5 mg) is a gonadotropin-releasing hormone (GnRH) agonist used in men with prostate cancer. This study investigated the prescription pattern of LAT in a real-world setting and its efficacy.</p><p><strong>Patients & methods: </strong>This was a retrospective review of patients in a tertiary center who were prescribed LAT for prostate cancer from January 2018 to March 2023 after the introduction of LAT in the territory. Demographic data were collected, and LAT prescription patterns were reviewed. These patterns included the indication and duration of prescription, testosterone suppression and characteristics of the primary prostate cancer.</p><p><strong>Results: </strong>A total of 237 prostate cancer patients were prescribed LAT in the study period. The indications for LAT included metastatic prostate cancer (50.6%), neoadjuvant/adjuvant therapy for radiotherapy (28.7%) and neoadjuvant therapy for radical prostatectomy (5.1%). Among the cohort, 41.4% of the patients were receiving short-acting triptorelin (11.25 mg) before LAT initiation, 15.2% were receiving other GnRH agonists, and 15.6% were receiving GnRH antagonists. The median age at the first dose of LAT and the median treatment duration were 72 (53-94) years and 30 (6-72) months, respectively. During the study period, 92.0% of the patients did not receive another form of hormonal treatment other than LAT. A total of 121 (51.1%) patients had their testosterone level checked after LAT initiation. The median time interval of testosterone measurement after LAT initiation was 8 (1-47) months, with 98.3% of the patients having a testosterone level < 1.7 nmol/L and 92.6% having a level < 0.7 nmol/L. Among the cohort, 1 patient stopped LAT due to hot flashes and muscle weakness.</p><p><strong>Conclusion: </strong>The LAT adherence rate was high in the setting of hormonal treatment for prostate cancer. Testosterone suppression was satisfactory after the initiation of LAT and was generally well tolerated.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"39"},"PeriodicalIF":1.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143499459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reverse placement of a double J ureteral stent improves lower urinary tract symptoms.","authors":"Goksel Bayar, Abdulmecit Yavuz, Yilmaz Ofluoglu, Caglar Yildirim","doi":"10.1186/s12894-025-01705-x","DOIUrl":"10.1186/s12894-025-01705-x","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical efficacy and patient-reported discomfort associated with traditional versus reverse placement of double-J ureteral stents (DJUS) in patients undergoing ureteroscopic stone removal.</p><p><strong>Materials and methods: </strong>This prospective, randomized, single-center, one blinded, controlled study. In the control group, the double-J stent was placed with its upper end facing laterally (towards the kidney) and its lower end facing medially (towards the bladder trigone), while in the study group, the reverse was done in a mirror manner. Patients in the study group were further subdivided based on the orientation of the upper and lower tips of the stent (B1: upper medial/lower lateral, B2: both medial, B3: both lateral). Patient discomfort was assessed using the Turkish version of the Ureteral Stent Symptom Questionnaire (T-USSQ), and secondary outcomes included postprocedural hydronephrosis, hematuria, and urinary tract infection.</p><p><strong>Results: </strong>A total of 120 patients were included and 60 patients to each the control and study groups. Forty patients were included in group B1, 8 in B2 and 12 in B3. The reverse placement group (Group B) reported significantly lower USSQ (p < 0.05) and reduced analgesic use compared to the control group. Midline crossing of the stent was significantly less frequent in the study group (11.7% vs. 30%; p = 0.013). Subgroup analysis revealed that the B1 and B3 groups had significantly lower analgesic usage and symptom scores compared to the control group, while the B2 group reported higher hydronephrosis and symptom scores.</p><p><strong>Conclusion: </strong>Reverse placement of DJUS, particularly when both stent ends are laterally positioned, may reduce stent-related discomfort. There is a need for a new stent design with both ends facing laterally, tentatively named \"ipsi-DJUS\".</p><p><strong>Trial registration: </strong>Turning the tip of the stent upside down may ease urinary symptoms\" is now listed on the ISRCTN registry with study registration number ISRCTN17937257 (Date of registration: 22/10/2024). Retrospectively registered.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"38"},"PeriodicalIF":1.7,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which localization method is optimal in ESWL: fluoroscopy or ultrasonography?","authors":"Dursun Baba, Necati Ekici, Arda Taşkın Taşkıran, Yusuf Şenoğlu, Alpaslan Yüksel, Ekrem Başaran, Mehmet Ali Özel, Ahmet Yıldırım Balık","doi":"10.1186/s12894-025-01716-8","DOIUrl":"10.1186/s12894-025-01716-8","url":null,"abstract":"<p><strong>Background: </strong>Urinary stone disease is a common urological disorder, particularly among middle-aged individuals. Extracorporeal Shock Wave Lithotripsy (ESWL) is often the first-line treatment for kidney and ureteral stones. Traditionally, fluoroscopy is used for stone targeting in ESWL, but it exposes patients and clinicians to radiation and cannot visualize non-opaque stones. Ultrasonographic targeting eliminates these issues. This study compares the advantages and disadvantages of fluoroscopy and ultrasound-targeted ESWL.</p><p><strong>Methods: </strong>At Düzce University Hospital, 100 patients with radio-opaque stones indicated for ESWL between February 2023 and February 2024 were divided into two groups. Group A underwent ESWL with fluoroscopic targeting, while Group B used ultrasonographic targeting. Patient demographics, stone size (measured by CT), and stone locations were recorded. The number of shocks per session, energy intensity (kV), and fluoroscopy time were noted for Group A. One week after each ESWL session, patients were evaluated by ultrasound or direct radiography. Success was defined as being stone-free or having ≤ 4 mm asymptomatic residual stones after up to four sessions. Failure was defined as no results after two sessions or the need for additional treatment.</p><p><strong>Results: </strong>The procedure success rate was 66% for men and 78% for women, with no statistically significant gender difference (p > 0.05). Stone locations were similar in both groups. Success rates were 66% in Group A and 74% in Group B, with no significant difference (p > 0.05). Successful procedures were associated with an average patient weight of 76.6 kg, stone size of 8.9 mm, and total energy of 12.2 kV, with significant differences compared to unsuccessful procedures (p < 0.04, p < 0.04, p < 0.001, respectively). No significant differences were found between Group A and Group B in terms of age, height, BMI, stone density (HU), and number of sessions (p > 0.05).</p><p><strong>Conclusion: </strong>Ultrasonography is as effective as fluoroscopy for imaging and focusing during ESWL treatment. It enhances the success of ESWL for non-opaque stones and reduces radiation exposure disadvantages.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"35"},"PeriodicalIF":1.7,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ectopic prostate tissue presenting as a bladder tumor in a young man- a case report.","authors":"Görkem Akça, Çiğdem Öztürk, Hakkı Uzun","doi":"10.1186/s12894-025-01712-y","DOIUrl":"10.1186/s12894-025-01712-y","url":null,"abstract":"<p><p>Ectopic prostate tissue, defined as the aberrant localization of prostate tissue, is often asymptomatic but may occasionally present with various clinical symptoms. A definitive diagnosis is established through surgical excision and subsequent histopathological analysis. This report discussess a case of ectopic prostate tissue identified in the bladder trigone of a 31-year-old patient who presented with lower urinary tract symptoms. Imaging studies revealed a suspicious lesion within the bladder, initially concerning for a potential tumor. Following cystoscopic examination, the lesion was transurethrally completely resected. Pathological analysis confirmed the diagnosis of ectopic prostate tissue, and the patient was subsequently monitored. This case highlights ectopic prostate tissue as a rare pathological condition that can present with clinical features resembling bladder tumors.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"36"},"PeriodicalIF":1.7,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis.","authors":"Henning Plage, Adrian Frericks, Sebastian Hofbauer, Kira Furlano, Sarah Weinberger, Florian Roßner, Simon Schallenberg, Sefer Elezkurtaj, Maximilian Lennartz, Andreas Marx, Henrik Samtleben, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek, Thorsten Ecke, Stefan Koch, Ronald Simon, Guido Sauter, Henrik Zecha, Joachim Weischenfeldt, Tobias Klatte, Sarah Minner, David Horst, Thorsten Schlomm, Martina Kluth","doi":"10.1186/s12894-025-01704-y","DOIUrl":"10.1186/s12894-025-01704-y","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to assess the impact of GATA3 binding protein (GATA3) gene copy number alterations on tumor aggressiveness, patient prognosis, and GATA3 protein expression in a large urothelial bladder cancer cohort.</p><p><strong>Methods: </strong>A tissue microarray containing over 2,700 urothelial bladder cancers (pTa-pT4) was analyzed retrospectively using dual-labeling fluorescence in-situ hybridization (FISH) with probes for GATA3 (10p14) and centromere 10. GATA3 copy number gains were categorized as GATA3 elevation (ratio GATA3/centromere ≥ 2/≤4), low-level amplification (ratio > 4/≤12), and high-level amplification (ratio > 12) and deletions were divided between homozygous and heterozygous.</p><p><strong>Results: </strong>GATA3 copy number gain was detected in 9.9% of 2,213 interpretable tumors, including 2.0% with GATA3 elevation, 3.2% with low-level amplification, and 4.7% with high-level amplification. The frequency of high-level amplification increased from pTa G2 low (0%) to pTa G3 tumors (12% [CI 0.07;0.21]; p < 0.0001 pTa G2 low vs. pTaG2 high) but decreased in advanced-stage carcinomas pT2-4 with 5.4% [CI 0.07;0.21] (p < 0.0001, pTa vs. pT2-4). In muscle-invasive carcinomas, GATA3 amplification was not linked to tumor aggressiveness or patient survival. Overall, no homozygous GATA3 deletion was detected and heterozygous GATA3 deletion was only observed in 1.1%; of 1,432 pT2-4 tumors without any association to cancer progression. While GATA3 copy number was significantly correlated with GATA3 expression (p < 0.0001), the relationship was not strong. Only 2.3% of GATA3-negative cancers had a deletion, and 42.1% of strong GATA3-expressing cancers exhibited high-level amplification.</p><p><strong>Conclusion: </strong>High-level GATA3 amplification is common in urothelial bladder cancer and correlates with grade progression in pTa tumors, while GATA3 deletion is rare. Neither amplification nor deletion appears to be the primary driver of GATA3 expression dysregulation.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"37"},"PeriodicalIF":1.7,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of holmium laser prostatectomy on surgical outcomes of primary bladder neck obstruction.","authors":"Hyomyoung Lee, Hyun Ju Jeong, Min Soo Choo, Sung Yong Cho, Seong Jin Jeong, Seung-June Oh","doi":"10.1186/s12894-025-01693-y","DOIUrl":"10.1186/s12894-025-01693-y","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study is to evaluate the efficacy and safety of holmium laser prostatectomy in patients diagnosed with primary bladder neck obstruction (PBNO), compared with patients with benign prostatic hyperplasia (BPH).</p><p><strong>Methods: </strong>We analyzed the databases of patients who underwent a holmium laser prostatectomy or enucleation of the prostate for PBNO and BPH between January 2018 and August 2022. PBNO was diagnosed primarily based on cystourethroscopic findings. Patients were followed up according to a regular protocol at 2 weeks, 3 mo, and 6 mo postoperatively.</p><p><strong>Results: </strong>In total, 28 and 447 patients with PBNO and BPH, respectively, were identified. Preoperative urodynamic studies showed that detrusor underactivity was significantly more prevalent in the PBNO group (78.6%) than in the BPH group (57.5%) (p < 0.01). Both PBNO and BPH groups showed significant improvements in the total International Prostate Symptom Score, Overactive Bladder Symptom Score, and maximum flow rate at 6 mo postoperatively compared with the preoperative values (p < 0.01). Subjective satisfaction 6 mo after operation was not significantly different between the PBNO and BPH groups (p > 0.05). Complications in the PBNO group included recatheterization (n = 1, 3.5%), with no patients requiring blood transfusion or transurethral coagulation.</p><p><strong>Conclusions: </strong>Holmium laser prostatectomy was effective and safe for patients with PBNO, with elevated subjective patient satisfaction.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"33"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035.","authors":"Hui Wei, Cong Zhu, Qiao Huang, Jun Yang, Yi-Tong Li, Yin-Gang Zhang, Bing-Hui Li, Hao Zi","doi":"10.1186/s12894-025-01715-9","DOIUrl":"10.1186/s12894-025-01715-9","url":null,"abstract":"<p><strong>Background: </strong>Benign prostatic hyperplasia (BPH) is a common male urological disease around the world. This study aimed to evaluate global, regional, and national burden of BPH from 1990 to 2021, and to forecast the incidence and prevalence of BPH to 2035.</p><p><strong>Methods: </strong>Using the data and methods of the Global Burden of Disease 2021, we presented the incidence, prevalence, and disability-adjusted life-years (DALYs) of BPH from 1990 to 2021. The trends of burden over time were assessed using estimated annual percentage changes. We applied Bayesian age-period-cohort model to forecast the incidence and prevalence of BPH to 2035.</p><p><strong>Results: </strong>In 2021, the global number of incident cases, prevalent cases, and DALYs of BPH were 137.88, 1125.02, and 22.36 per 100,000 populations, respectively. From 1990 to 2021, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALYs rate (ASDR) of BPH remained stable. The highest ASIR, ASPR, and ASDR were recorded in Eastern Europe in 2021. Nationally, China had the highest number of incident cases, prevalent cases, and DALYs of BPH. With the increase of socio-demographic index, the trends of ASIR, ASPR, and ASDR all exhibit an initial rise followed by a gradual decline. The global incidence and prevalence are expected to increase from 962.42 to 7878.68 per 100,000 populations in 2022 to 998.55 and 8620.60 per 100,000 populations in 2035, respectively.</p><p><strong>Conclusions: </strong>The persistent burden of BPH continues to pose a critical public health challenge. The escalating prevalence among middle-aged and elderly populations underscores the imperative to tackle this widespread condition.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"34"},"PeriodicalIF":1.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles and therapeutic potential of the SLC family in prostate cancer-literature review.","authors":"Yuanzhi Fu, Junhao Chen, Xingcheng Zhu, Mingxia Ding, Haifeng Wang, Shi Fu","doi":"10.1186/s12894-025-01714-w","DOIUrl":"10.1186/s12894-025-01714-w","url":null,"abstract":"<p><p>Prostate cancer (PCa) is one of the most common malignancies in men worldwide. Despite advances in treatment, many patients develop resistance to conventional therapies. Solute carrier (SLC) proteins, as transmembrane transporters, have recently emerged as potential therapeutic targets due to their role in tumor metabolism and progression. This review summarizes the key roles of six SLC proteins in PCa, including their involvement in metabolic reprogramming, regulation of signaling pathways, and effects on the tumor microenvironment. Although targeting of SLC family members in prostate cancer remains an underexplored area, the growing body of evidence suggests that it holds potential for future development.</p>","PeriodicalId":9285,"journal":{"name":"BMC Urology","volume":"25 1","pages":"32"},"PeriodicalIF":1.7,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}